A fourth dose of bivalent or monovalent BA.1-adapted BNT162b2 vaccines was safe and elicited robust neutralizing responses in adults aged 18 to 55 years.

The most common cancer in women — and one of the deadliest — may have finally met its match. Development of a breakthrough vaccine researchers say could eradicate breast cancer by 2030 wrapped up ...

RA patients on upadacitinib and methotrexate showed robust antibody and T-cell responses to the recombinant zoster vaccine over 60 weeks. The vaccine maintained a satisfactory humoral response in 71.4 ...

Researchers at University of California San Diego School of Medicine have found that a natural fungal supplement taken at the ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Withholding Janus kinase or interleukin-17 inhibitors from patients with rheumatoid arthritis or ...

Median 4-week preF IgG fold rise was 4.21; 61% of participants achieved seroconversion. (HealthDay News) — For immunocompromised individuals, antibody response to respiratory syncytial virus (RSV) ...